enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. GLP-1 Drugs Like Wegovy, Zepbound Less Effective Than ... - AOL

    www.aol.com/glp-1-drugs-wegovy-zepbound...

    After 36 weeks of weekly injections of tirzepatide, another GLP-1 drug, people lost an average of 21.1% of their weight. Tirzepatide also targets another hormone, GIP, making it a dual-acting drug.

  3. Largest-ever Ozempic and GLP-1 drug study finds they lower ...

    www.aol.com/finance/largest-ever-ozempic-glp-1...

    As the GLP-1 patients in Al-Aly’s study were all veterans, with full drug coverage, their retention rate was higher—roughly 70% after a year. How the study’s results will be interpreted or ...

  4. Ozempic shown to reduce drinking in first trial in alcohol ...

    www.aol.com/news/ozempic-shown-reduce-drinking...

    Semaglutide, sold by Novo Nordisk as Ozempic for type 2 diabetes and Wegovy for obesity, is part of a class of drugs known as GLP-1 receptor agonists, mimicking the hormone GLP-1 to reduce ...

  5. Anti-obesity medication - Wikipedia

    en.wikipedia.org/wiki/Anti-obesity_medication

    GLP-1 agonists such as tirzepatide, semaglutide, and liraglutide slow gastric emptying and also have neurologically driven effects on appetite. [14] It is unknown if GLP-1 agonists or dual/triple agonists of GLP-1 and/or the glucagon or GIP receptors act solely by reducing energy intake or if they also increase energy expenditure. [15]

  6. GLP-1 receptor agonist - Wikipedia

    en.wikipedia.org/wiki/GLP-1_receptor_agonist

    Native GLP-1 is a peptide hormone with a half-life of two minutes because it is rapidly cleared by the enzyme dipeptidyl peptidase-4. [29] As a result, different GLP-1 agonist drugs are modified in various ways to extend the half-life, resulting in drugs that can be dosed multiple times per day, daily, weekly, or less often. [29]

  7. Cagrilintide/semaglutide - Wikipedia

    en.wikipedia.org/wiki/Cagrilintide/semaglutide

    In December 2024, Novo Nordisk announced the results of REDEFINE 1, one of their series of Phase III trials, testing weekly cagrilintide 2.4 mg and semaglutide 2.4 mg individually and together versus placebo in obese or overweight subjects with one or more comorbidities. [7]

  8. Aleniglipron - Wikipedia

    en.wikipedia.org/wiki/Aleniglipron

    Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. [1] It is delivered orally and is in a Phase II trial as of 2023.

  9. Diet in diabetes - Wikipedia

    en.wikipedia.org/wiki/Diet_in_diabetes

    [1] [2] This is due to a lack of long term high-quality studies on this subject matter. [1] [2] For overweight and obese people with diabetes, the most important aspect of any diet is that it results in loss of body fat. [1] [2] Losing body fat has been proven to improve blood glucose control and lower insulin levels. [1] [2]